Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15753734 | 0.95 | SMN1; SMN2 (0.53) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL368274 | 0.83 | USP2 (0.44) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL3154651 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL21869507 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL6293470 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL10157145 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL9506534 | 0.80 | LMNA (0.44) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL24575950 | 0.80 | HPGD (0.72) | SMN1; SMN2USP2HPGDTP53ALOX12 | |
| SCHEMBL183843 | 0.80 | — | — | |
| SCHEMBL6061649 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2USP2HPGDTP53ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264622-A1 | MULTI-COMPONENT RESPONSIVE COPOLYMERS AND APPLICATIONS THEREOF | AESCULA TECH, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250382404-A1 | MULTI-COMPONENT RESPONSIVE COPOLYMERS AND APPLICATIONS THEREOF | AESCULATECH INC (US) | 2025-12-18 | — | — | US | claimed |
| CN-115135307-B | Cell delivery vehicle | 株式会社ITO | 2024-11-22 | — | — | CN | claimed |
| US-11773300-B2 | Acrylic adhesive compositions and methods of making same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-10-03 | — | — | US | claimed |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | ITO, KABUSIKIKAISYA (JP) | 2023-02-23 | — | — | US | claimed |
| CN-115135307-A | Carrier for cell delivery | 株式会社ITO | 2022-09-30 | — | — | CN | claimed |
| US-20200255700-A1 | ACRYLIC ADHESIVE COMPOSITIONS AND METHODS OF MAKING SAME | DOW GLOBAL TECHNOLOGIES LLC | 2020-08-13 | — | — | US | claimed |
| EP-3688109-A1 | ACRYLIC ADHESIVE COMPOSITIONS AND METHODS OF MAKING SAME | Dow Global Technologies LLC (US) | 2020-08-05 | — | — | EP | claimed |
| CN-108102918-B | Culture dish device and culture method of cell membrane | 京东方科技集团股份有限公司 | 2020-07-07 | — | — | CN | claimed |
| US-20200032192-A1 | CULTURE DEVICE AND CELL CULTURE METHOD USING SAME | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2020-01-30 | — | — | US | claimed |
| CN-101117423-A | Thermo-responsive blends and uses thereof | CORNING INC (US) | 2008-02-06 | — | — | CN | claimed |
| EP-1873205-A1 | Thermo-responsive blends and uses thereof | CORNING INCORPORATED (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2007144356-A1 | THERMO-RESPONSIVE BLENDS AND USES THEREOF | CORNING INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2006101548-A2 | POSTPARTUM CELLS DERIVED FROM UMBILICAL CORD TISSUE, AND METHODS OF MAKING, CULTURING, AND USING THE SAME | ETHICON, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| WO-2006083394-A2 | POSTPARTUM CELLS DERIVED FROM PLACENTAL TISSUE, AND METHODS OF MAKING, CULTURING, AND USING THE SAME | ETHICON, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060171930-A1 | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC | 2006-08-03 | — | — | US | claimed |
| US-20060166361-A1 | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same | ETHICON, INC. | 2006-07-27 | — | — | US | claimed |
| US-5298554-A | Heating and solution polymerizing | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | claimed |
| EP-0552380-A1 | CELL CULTURE SUPPORT, PRODUCTION THEREOF, AND PRODUCTION OF CELL CLUSTER USING SAME | Kao Corporation (JP) | 1993-07-28 | — | — | EP | claimed |
| US-5093030-A | Emulsion polymerizing an acrylamide, crosslinking, removing surfactant | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1992-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171930-A1 | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same | PGF, PLAUR, CD68 | SMN1; SMN2 1658/4885USP2 1579/4885HPGD 749/4885 |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | CTSA, ATG4A, ATG7 | SMN1; SMN2 3062/4885USP2 199/4885HPGD 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.